OpenAI Buys Orchestra Bio, Pushing AI Agents Into Drug Development
OpenAI has bought Orchestra Bio, a San Francisco startup that makes AI agents to help drug companies manage complex drug development projects and keep them on schedule. OpenAI will add the company's team and technology to its Rosalind platform for life sciences. The price of the purchase was not shared.
The deal was announced on Tuesday on OpenAI's website. It is the latest move by a major AI company to build software for specific industries, including drug development. Developing new medicines can take years and cost billions of dollars.
Orchestra's AI agents handle the planning and tracking work needed to develop medicines. They monitor studies, track project schedules and budgets, and warn teams about possible delays before they lead to bigger problems. When a problem appears, the software collects useful information and compares possible ways to deal with it. Scientists and project leaders make the final decisions. OpenAI said the combined team will build agents that connect scientific findings with the decisions and follow-up studies needed to turn promising results into medicines.
"Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner," OpenAI said in its announcement.
Orchestra was founded in the fall of 2022. According to Caplight data cited in reports, it had raised about $20 million by 2025. Its backers included Andreessen Horowitz, Definition Capital, Insight Partners and 8VC. Orchestra Bio is not related to Orchestra BioMed, a separate medical device company listed on Nasdaq under the stock symbol OBIO.
The purchase adds to Rosalind, a family of AI models that OpenAI introduced in April for biology, chemistry and drug discovery. At first, access was limited to approved business customers in the United States. A related product, Rosalind Workbench, connects the models to scientific tools and data so researchers can plan experiments and study their results. OpenAI says Rosalind customers include Moderna (MRNA) and Novo Nordisk (NVO).
OpenAI says its goal is to save time. The company says bringing a new medicine from the first idea to approval in the United States can take up to 15 years. Every month saved could mean patients get a treatment sooner and the company making it can start earning money earlier. Bringing one approved drug to market can cost more than $2.6 billion, and fewer than 10% of drug candidates that begin testing in people ever reach pharmacy shelves.
Many delays happen outside the laboratory. Drug development teams must coordinate work between their own departments and outside partners. These partners include contract research organizations, which run studies, and contract manufacturers, which make experimental compounds. They often use computer systems that cannot easily share information with one another.
OpenAI has made clear that it wants to earn money from science in ways that go beyond subscriptions. In a January blog post, Chief Financial Officer Sarah Friar wrote that as AI spreads into drug discovery and similar fields, companies will share in the value it creates through licensing, intellectual property agreements and payments based on results.
The move is similar to the strategy of rival Anthropic. In April, Anthropic bought AI biotechnology startup Coefficient Bio for about $400 million. In June, it launched a research platform called Claude Science. In September, Anthropic said its Claude model helped discover a previously unknown enzyme system that resembles CRISPR, a gene-editing tool. However, some scientists argued that the importance of this finding had been overstated.
OpenAI has been building a wider range of science and health products. In January, it launched ChatGPT Health, which lets users connect their medical records to the chatbot, and bought medical records startup Torch for a reported $100 million. That same month, it turned another purchase, a scientific writing tool called Crixet, into a research platform called Prism. Five days before the Orchestra deal, OpenAI introduced a Rosalind Academic Plan that offers eligible university laboratories in the United States up to 30 free seats for as long as 12 months.
OpenAI has not said when Orchestra's AI agents will become part of Rosalind.
For investors, the deal offers a small but useful sign of how AI companies are preparing for possible public stock market listings. Several AI investors told Axios that an important question for any AI company planning to go public is how much it can grow into markets beyond coding and cybersecurity. Life sciences could be an attractive market because customers have large budgets, the work can be valuable, and companies can make a convincing case that their technology could improve human health.
The deal also matters to established drugmakers and the software companies that serve them. If AI companies that build tools for many different tasks can take over the work of coordinating clinical development, they could become partners to large pharmaceutical companies. They could also compete with specialized software providers that manage clinical trials and other clinical work.
For startups building AI tools for specific industries, the Orchestra deal brings both opportunity and risk. These startups have long worried that a large AI company might release a feature that makes their products unnecessary almost overnight. In this case, the startup was bought rather than pushed out of the market. This shows that being acquired remains a possible way for a startup to exit, but it also shows that large AI companies are looking to buy other businesses.
Key details of the deal:
| Item | Detail |
|---|---|
| Acquirer | OpenAI |
| Target | Orchestra Bio (San Francisco) |
| Announced | Tuesday, Oct. 20 |
| Purchase price | Not disclosed |
| Target funding to date | About $20 million (Caplight data) |
| Backers | Andreessen Horowitz, Definition Capital, Insight Partners, 8VC |
| Founded | Fall 2022 |
| Integration | Rosalind models and Rosalind Workbench |
| Named Rosalind customers | Moderna (MRNA), Novo Nordisk (NVO) |
Note: Orchestra Bio is not related to Orchestra BioMed, a medical device company listed on Nasdaq under the stock symbol OBIO.
The main reason for the deal is that delays in drug development often come from managing the work, not just from doing the science. AI models have already shown promise in predicting protein structures and creating molecules. But keeping a project that lasts several years on schedule still requires a lot of work by people. Orchestra says its AI agents can track these tasks continuously and warn teams about problems while there is still time to respond.
It is not yet clear whether this technology will actually shorten drug development. The figures OpenAI cites—10 to 15 years and more than $2.6 billion for each approved drug—show how difficult and costly the process is. Many drug candidates fail in later stages of testing, and delays can reduce the time a company has to sell a drug while its patent protects it from competitors. Software that saves months on scheduling and reporting could help, but it addresses problems with coordination rather than the scientific risks that cause most drug candidates to fail.
The deal also increases competition between OpenAI and Anthropic, which are now competing in areas far beyond chatbots. Both companies want to win business from organizations that pay for AI tools for scientific research. Each is building a collection of models, workbenches and AI agents for researchers. Anthropic's purchase of Coefficient Bio in April and launch of Claude Science in June helped set the pace. OpenAI is responding with Rosalind and its purchase of Orchestra.
For now, OpenAI is keeping the financial details private and has not announced when Orchestra's tools will become available to all Rosalind users. The company's goal is to make its technology part of the process that turns a laboratory discovery into an approved treatment, and to earn money from the value it helps create.